Skip to main content
. 2017 Mar 6;38(4):581–590. doi: 10.1038/aps.2016.164

Table 4. Stratification analysis of the association between lncRNA polymorphisms and gastrointestinal toxicity.

Gene SNP Subgroup Additive
 Dominant
 Recessive
      OR (95% CI) P OR (95% CI) P OR (95% CI) P
ANRIL rs1333049 Male 0.695 (0.466, 1.035) 0.073 0.510 (0.285, 0.913) 0.023* 0.825 (0.422, 1.603) 0.566
    NSCLC 0.599 (0.399, 0.899) 0.013* 0.475 (0.264, 0.855) 0.013* 0.584 (0.288, 1.184) 0.136
    ADC 0.520 (0.291, 0.928) 0.027* 0.564 (0.241, 1.320) 0.187 0.279 (0.090, 0.864) 0.027*
    SCC 0.635 (0.344, 1.175) 0.148 0.327 (0.137, 0.784) 0.012* 1.205 (0.443, 3.279) 0.715
    Cisplatina 0.625 (0.425, 0.919) 0.017* 0.544 (0.308, 0.963) 0.037* 0.549 (0.280, 1.074) 0.080
    GP 0.564 (0.328, 0.970) 0.038* 0.441 (0.197, 0.987) 0.046* 0.518 (0.203, 1.322) 0.169
    Smoke 0.622 (0.394, 0.982) 0.041 0.428 (0.221, 0.828) 0.012* 0.756 (0.355, 1.608) 0.467
    Advanced NSCLC 0.660 (0.451, 0.967) 0.033* 0.572 (0.327, 0.999) 0.050* 0.603 (0.308, 1.181) 0.140
H19 rs2107425 Less 57b 0.874 (0.536, 1.426) 0.591 1.389 (0.712, 2.711) 0.336 0.182 (0.047, 0.812) 0.026*
    ADC 0.673 (0.374, 1.208) 0.184 0.885 (0.411, 1.909) 0.756 0.124 (0.015, 0.995) 0.049*
    NSCLC 0.790 (0.519, 1.201) 0.270 1.078 (0.610, 1.904) 0.796 0.228 (0.067, 0.778) 0.018*
    SCLC 2.541 (0.847, 7.619) 0.096 5.937 (1.049, 32.230) 0.039* 1.173 (0.154, 9.150) 0.879
  rs2839698 More 57c 1.483 (0.819, 2.687) 0.194 1.188 (0.555, 2.541) 0.657 4.037 (1.168, 13.950) 0.027*
    Female 2.223 (1.033, 4.783) 0.041* 2.796 (1.011, 7.736) 0.048* 2.842 (0.544, 14.860) 0.216
MALAT1 rs619586 Smoke 1.978 (1.052, 3.721) 0.034* 2.373 (1.156, 4.874) 0.019* 1.234 (0.118, 12.910) 0.861
    More 57c 2.339 (1.082, 5.055) 0.031* 3.005 (1.295, 6.971) 0.010* 2.230 (0.636, 20.750) 0.998
HOTAIR rs1899663 More 57c 0.501 (0.241, 1.042) 0.064 0.369 (0.157, 0.868) 0.022* 1.164 (0.222, 6.095) 0.857
  rs7958904 NSCLC 0.553 (0.349, 0.876) 0.011* 0.525 (0.303, 0.908) 0.021* 0.341 (0.093, 1.238) 0.102
    SCC 0.436 (0.199, 0.955) 0.038* 0.404 (0.167, 0.978) 0.044* 0.306 (0.029, 3.226) 0.324
    Cisplatina 0.514 (0.333, 0.793) 0.003* 0.451 (0.269, 0.756) 0.003* 0.429 (0.140, 1.320) 0.140
    Advanced NSCLC 0.608 (0.395, 0.937) 0.024* 0.591 (0.354, 0.986) 0.044* 0.375 (0.106, 1.329) 0.129
MEG3 rs116907618 NSCLC 2.178 (1.197, 3.965) 0.011* 2.195 (1.135, 4.242) 0.019* 7.351 (0.632, 85.500) 0.111
    SCC 3.538 (1.269, 9.864) 0.016* 3.538 (1.269, 9.864) 0.016* 3.684 (0.549, 10.269) 0.887
    GP 2.735 (1.192, 6.274) 0.018* 2.695 (1.131, 6.421) 0.025* 2.440 (0.789, 12.872) 0.989
    Advanced NSCLC 2.118 (1.196, 3.753) 0.010* 2.149 (1.153, 4.007) 0.016* 6.193 (0.539,71.190) 0.143
POLR2E rs3787016 More 57c 1.726 (1.019, 2.924) 0.042* 1.320 (0.560,3.111) 0.526 3.159 (1.402,7.121) 0.006*
    Smoke 0.714 (0.466, 1.096) 0.124 0.479 (0.249,0.921) 0.027* 0.898 (0.442,1.825) 0.766
    Male 1.430 (0.972, 2.105) 0.070 1.132 (0.603,2.124) 0.699 2.147 (1.196,3.853) 0.010*

Abbreviations: SNP, single nucleotide polymorphism; OR, odd ratio; CI, confidence interval; NSCLC, non-small-cell lung cancer; ADC, adenocarcinoma; SCLC, small-cell lung cancer; SCC, squamous-cell carcinoma; GP, platinum+gemcitabine. Cisplatina, cisplatin-based chemotherapy. Less 57b, age less 57. More 57c, age more 57.

*P<0.05.